Trial Profile
Multicenter, Open Label Extension Study of 8 mg PEG-uricase in Subjects Who Completed Protocols C0405 or C0406 for Symptomatic Gout
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Pegloticase (Primary)
- Indications Gout
- Focus Therapeutic Use
- Sponsors Savient Pharmaceuticals
- 15 Nov 2023 Results of analysis assessing potential baseline factors that may influence urate-lowering response to pegloticas using data from Phase 3 pegloticase registration and MIRROR RCT2 trials presented at the ACR Convergence 2023
- 06 Jan 2021 Results of post-hoc analysis of two studies (NCT00325195 & NCT01356498) assessing factors associated with gout flares in subjects treated with pegloticase, published in the Clinical and Experimental Rheumatology.
- 21 Mar 2019 According to an AMPEL BioSolutions media release, results evaluating the characteristics and response to pegloticase of patients with chronic refractory gout with and without clinically apparent tophi, from two clinical trials, (NCT00325195, NCT01356498) were published in Rheumatology.